Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) - Pipeline Review, H2 2016
Description-
Global
Markets Directs, Carcinoembryonic Antigen Related Cell Adhesion
Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100
or CD66e or CEACAM5) - Pipeline Review, H2 2016, provides in depth
analysis on Carcinoembryonic Antigen Related Cell Adhesion Molecule 5
(Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or
CEACAM5) targeted pipeline therapeutics.
The
report provides comprehensive information on the Carcinoembryonic
Antigen Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or
CEA or Meconium Antigen 100 or CD66e or CEACAM5) , targeted
therapeutics, complete with analysis by indications, stage of
development, mechanism of action (MoA), route of administration (RoA)
and molecule type. The report also covers the descriptive
pharmacological action of the therapeutics, its complete research and
development history and latest news and press releases. Additionally,
the report provides an overview of key players involved in
Carcinoembryonic Antigen Related Cell Adhesion Molecule 5
(Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or
CEACAM5) targeted therapeutics development and features dormant and
discontinued projects.
Global
Markets Directs report features investigational drugs from across
globe covering over 20 therapy areas and nearly 3,000 indications.
The report is built using data and information sourced from Global
Markets Directs proprietary databases, company/university websites,
clinical trial registries, conferences, SEC filings, investor
presentations and featured press releases from company/university
sites and industry-specific third party sources. Drug profiles
featured in the report undergoes periodic review following a
stringent set of processes to ensure that all the profiles are
updated with the latest set of information. Additionally, various
dynamic tracking processes ensure that the most recent developments
are captured on a real time basis.
Scope
-
The report provides a snapshot of the global therapeutic landscape
for Carcinoembryonic Antigen Related Cell Adhesion Molecule 5
(Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or
CEACAM5)
-
The report reviews Carcinoembryonic Antigen Related Cell Adhesion
Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100
or CD66e or CEACAM5) targeted therapeutics under development by
companies and universities/research institutes based on information
derived from company and industry-specific sources
-
The report covers pipeline products based on various stages of
development ranging from pre-registration till discovery and
undisclosed stages
-
The report features descriptive drug profiles for the pipeline
products which includes, product description, descriptive MoA, R&D
brief, licensing and collaboration details & other developmental
activities
-
The report reviews key players involved in Carcinoembryonic Antigen
Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or
Meconium Antigen 100 or CD66e or CEACAM5) targeted therapeutics and
enlists all their major and minor projects
-
The report assesses Carcinoembryonic Antigen Related Cell Adhesion
Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100
or CD66e or CEACAM5) targeted therapeutics based on mechanism of
action (MoA), route of administration (RoA) and molecule type
Reasons
to buy
-
Gain strategically significant competitor information, analysis, and
insights to formulate effective R&D strategies
-
Identify emerging players with potentially strong product portfolio
and create effective counter-strategies to gain competitive advantage
-
Identify and understand the targeted therapy areas and indications
for Carcinoembryonic Antigen Related Cell Adhesion Molecule 5
(Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or
CEACAM5)
-
Identify the use of drugs for target identification and drug
repurposing
-
Identify potential new clients or partners in the target demographic
-
Develop strategic initiatives by understanding the focus areas of
leading companies
-
Plan mergers and acquisitions effectively by identifying key players
and its most promising pipeline therapeutics
-
Devise corrective measures for pipeline projects by understanding
Carcinoembryonic Antigen Related Cell Adhesion Molecule 5
(Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or
CEACAM5) development landscape
Comments
Post a Comment